Date: 2012-11-06
Type of information: Grant
Company: Arecor (UK)
Investors: Biomedical Catalyst Fund (UK)
Amount: £785,000 (€ 984 500)
Funding type: grant
Planned used: The funds will be used to accelerate the development of high concentration antibodies to allow more convenient administration of Arecor's therapeutic products.
Others: Cambridge biotech company Arecor has been awarded £785,000 from the government-backed Biomedical Catalyst Fund to accelerate the development of high concentration antibodies to allow more convenient administration of their future therapeutic medicines and reduce healthcare costs.Tom Saylor, CEO of Arecor, said the award will go towards a £1.3 million project to drive forward their innovative research.
Arecor is a pioneer in the stabilisation of biologic molecules. Many proteins, peptides or vaccines are too unstable in liquid form to develop ready-to-use drugs or are unstable at high concentrations. From its work on over 60 biological molecules, Arecor has developed proprietary technologies to address most of the pathways that lead these products to degrade in storage.The company has recently demonstrated Proof of Concept in developing stable aqueous formulations of a number of high concentration monoclonal antibodies.
Therapeutic area:
